|
|
Recent studies of atomic-resolution structures of tau protein and structure-based inhibitors |
Lili Zhu, Zhenyu Qian( ) |
Key Laboratory of Exercise and Health Sciences (Ministry of Education) and School of Kinesiology, Shanghai University of Sport, Shanghai 200438, China |
|
|
Abstract Background: Alzheimer’s disease (AD) is one of the most popular tauopathies. Neurofibrillary tangles and senile plaques are widely recognized as the pathological hallmarks of AD, which are mainly composed of tau and β-amyloid (Aβ) respectively. Recent failures of drugs targeting Aβ have led scientists to scrutinize the crucial impact of tau in neurodegenerative diseases. Mutated or abnormal phosphorylated tau protein loses affinity with microtubules and assembles into pathological accumulations. The aggregation process closely correlates to two amyloidogenic core of PHF6 (306VQIVYK311) and PHF6* (275VQIINK280) fragments. Moreover, tau accumulations display diverse morphological characteristics in different diseases, which increases the difficulty of providing a unifying neuropathological criterion for early diagnosis. Results: This review mainly summarizes atomic-resolution structures of tau protein in the monomeric, oligomeric and fibrillar states, as well as the promising inhibitors designed to prevent tau aggregation or disaggregate tau accumulations, recently revealed by experimental and computational studies. We also systematically sort tau functions, their relationship with tau structures and the potential pathological processes of tau protein. Conclusion: The current progress on tau structures at atomic level of detail expands our understanding of tau aggregation and related pathology. We discuss the difficulties in determining the source of neurotoxicity and screening effective inhibitors. We hope this review will inspire new clues for designing medicines against tau aggregation and shed light on AD diagnosis and therapies.
|
Keywords
tau
paired helical filaments
inhibitor
cryo-electron microscopy
molecular dynamics simulation
|
Corresponding Author(s):
Zhenyu Qian
|
About author: Mingsheng Sun and Mingxiao Yang contributed equally to this work. |
Just Accepted Date: 30 November 2021
Online First Date: 14 January 2022
Issue Date: 28 March 2022
|
|
1 |
Q., Chen Y., Du K., Zhang Z., Liang J., Li H., Yu R., Ren J., Feng Z., Jin F. Li et al.. (2018). A tau-targeted multifunctional nanocomposite for combinational therapy of Alzheimer’s disease. ACS Nano, 12 : 1321–1338
https://doi.org/10.1021/acsnano.7b07625
|
2 |
J., Zeisel K. Bennett (2020). World Alzheimer report 2020: Design, dignity, dementia: dementia-related design and the built environment. Accessed: February 1, 2021
|
3 |
Association Alzheimer’s (2021). 2021 Alzheimer’s disease facts and figures. Alzheimers Dement., 17 : 327–406
https://doi.org/10.1002/alz.12328
|
4 |
J. Grandy (2013). Melatonin: Therapeutic intervention in mild cognitive impairment and Alzheimer disease. J. Neurol. Neurophysiol., 4 : 148
https://doi.org/10.4172/2155-9562.1000148
|
5 |
M. S., Uddin M. T., Kabir A., Al Mamun M. M., Abdel-Daim G. E. Barreto G. Ashraf (2019). APOE and Alzheimer’s disease: Evidence mounts that targeting APOE4 may combat Alzheimer’s pathogenesis. Mol. Neurobiol., 56 : 2450–2465
https://doi.org/10.1007/s12035-018-1237-z
|
6 |
J. A. Hardy G. Higgins (1992). Alzheimer’s disease: the amyloid cascade hypothesis. Science, 256 : 184–185
https://doi.org/10.1126/science.1566067
|
7 |
K., Rajasekhar M. Chakrabarti (2015). Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer’s disease. Chem. Commun. (Camb.), 51 : 13434–13450
https://doi.org/10.1039/C5CC05264E
|
8 |
K. Rajasekhar (2018). Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer’s disease. RSC Advances, 8 : 23780–23804
https://doi.org/10.1039/C8RA03620A
|
9 |
R., van der Kant L. S. B. Goldstein (2020). Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nat. Rev. Neurosci., 21 : 21–35
https://doi.org/10.1038/s41583-019-0240-3
|
10 |
E. E. Congdon E. Sigurdsson (2018). Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol., 14 : 399–415
https://doi.org/10.1038/s41582-018-0013-z
|
11 |
S. M. Alavi Naini (2015). Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies? Oxid. Med. Cell. Longev., 2015 : 151979
https://doi.org/10.1155/2015/151979
|
12 |
J. S., Kerr B. A., Adriaanse N. H., Greig M. P., Mattson M. Z., Cader V. A. Bohr E. Fang (2017). Mitophagy and Alzheimer’s disease: Cellular and molecular mechanisms. Trends Neurosci., 40 : 151–166
https://doi.org/10.1016/j.tins.2017.01.002
|
13 |
M. A. Busche B. Hyman (2020). Synergy between amyloid-β and tau in Alzheimer’s disease. Nat. Neurosci., 23 : 1183–1193
https://doi.org/10.1038/s41593-020-0687-6
|
14 |
A. Mullard (2021). Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating. Nat. Rev. Drug Discov., 20 : 3–5
https://doi.org/10.1038/d41573-020-00217-7
|
15 |
L. Dehmelt (2005). The MAP2/Tau family of microtubule-associated proteins. Genome Biol., 6 : 204
https://doi.org/10.1186/gb-2004-6-1-204
|
16 |
L., Jameson T., Frey B., Zeeberg F. Dalldorf (1980). Inhibition of microtubule assembly by phosphorylation of microtubule-associated proteins. Biochemistry, 19 : 2472–2479
https://doi.org/10.1021/bi00552a027
|
17 |
Y., Gu F. Oyama (1996). Tau is widely expressed in rat tissues. J. Neurochem., 67 : 1235–1244
https://doi.org/10.1046/j.1471-4159.1996.67031235.x
|
18 |
L. Bakota (2016). Tau biology and tau-directed therapies for Alzheimer’s disease. Drugs, 76 : 301–313
https://doi.org/10.1007/s40265-015-0529-0
|
19 |
T., Guo W. Noble D. Hanger (2017). Roles of tau protein in health and disease. Acta Neuropathol., 133 : 665–704
https://doi.org/10.1007/s00401-017-1707-9
|
20 |
M., Goedert M. G., Spillantini R., Jakes D. Rutherford R. Crowther (1989). Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron, 3 : 519–526
https://doi.org/10.1016/0896-6273(89)90210-9
|
21 |
E. Mandelkow (2012). Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med., 2 : a006247
https://doi.org/10.1101/cshperspect.a006247
|
22 |
C. Conde (2009). Microtubule assembly, organization and dynamics in axons and dendrites. Nat. Rev. Neurosci., 10 : 319–332
https://doi.org/10.1038/nrn2631
|
23 |
M. D., Weingarten A. H., Lockwood S. Y. Hwo M. Kirschner (1975). A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. USA, 72 : 1858–1862
https://doi.org/10.1073/pnas.72.5.1858
|
24 |
T. G., Castro F. D. Munteanu (2019). Electrostatics of tau protein by molecular dynamics. Biomolecules, 9 : 116
https://doi.org/10.3390/biom9030116
|
25 |
E. H., Kellogg N. M. A., Hejab S., Poepsel K. H., Downing F. DiMaio (2018). Near-atomic model of microtubule-tau interactions. Science, 360 : 1242–1246
https://doi.org/10.1126/science.aat1780
|
26 |
Qiang, L., Sun, X., Austin, T. O., Muralidharan, H., Jean, D. C., Liu, M., Yu, W., and Baas, P. W. (2018) Tau does not stabilize axonal microtubules but rather enables them to have long labile domains. Curr. Biol., 28, 2181−2189. e4
|
27 |
P. W. Baas (2019). Tau: It’s not what you think. Trends Cell Biol., 29 : 452–461
https://doi.org/10.1016/j.tcb.2019.02.007
|
28 |
G. B., Witman D. W., Cleveland M. D. Weingarten M. Kirschner (1976). Tubulin requires tau for growth onto microtubule initiating sites. Proc. Natl. Acad. Sci. USA, 73 : 4070–4074
https://doi.org/10.1073/pnas.73.11.4070
|
29 |
B., Zhang J., Carroll J. Q., Trojanowski Y., Yao M., Iba J. S., Potuzak A. M., Hogan S. X., Xie C., Ballatore A. B. Smith III et al.. (2012). The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci., 32 : 3601–3611
https://doi.org/10.1523/JNEUROSCI.4922-11.2012
|
30 |
A., Mietelska-Porowska U., Wasik M., Goras A. Filipek (2014). Tau protein modifications and interactions: their role in function and dysfunction. Int. J. Mol. Sci., 15 : 4671–4713
https://doi.org/10.3390/ijms15034671
|
31 |
M. Medina (2014). The role of extracellular tau in the spreading of neurofibrillary pathology. Front. Cell. Neurosci., 8 : 113
https://doi.org/10.3389/fncel.2014.00113
|
32 |
A., Elie E., Prezel C., rin E., Denarier S., Ramirez-Rios L., Serre A., Andrieux A., Fourest-Lieuvin L. Blanchoin (2015). Tau co-organizes dynamic microtubule and actin networks. Sci. Rep., 5 : 9964
https://doi.org/10.1038/srep09964
|
33 |
M., Violet L., Delattre M., Tardivel A., Sultan A., Chauderlier R., Caillierez S., Talahari F., Nesslany B., Lefebvre E. Bonnefoy et al.. (2014). A major role for tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions. Front. Cell. Neurosci., 8 : 84
https://doi.org/10.3389/fncel.2014.00084
|
34 |
A., Sultan F., Nesslany M., Violet S., gard A., Loyens S., Talahari Z., Mansuroglu D., Marzin N., Sergeant S. Humez et al.. (2011). Nuclear tau, a key player in neuronal DNA protection. J. Biol. Chem., 286 : 4566–4575
https://doi.org/10.1074/jbc.M110.199976
|
35 |
B., Bulic M., Pickhardt E. M. Mandelkow (2010). Tau protein and tau aggregation inhibitors. Neuropharmacology, 59 : 276–289
https://doi.org/10.1016/j.neuropharm.2010.01.016
|
36 |
P. M., Seidler D. R., Boyer J. A., Rodriguez M. R., Sawaya D., Cascio K., Murray T. Gonen D. Eisenberg (2018). Structure-based inhibitors of tau aggregation. Nat. Chem., 10 : 170–176
https://doi.org/10.1038/nchem.2889
|
37 |
B., Nizynski W. Dzwolak (2017). Amyloidogenesis of tau protein. Protein Sci., 26 : 2126–2150
https://doi.org/10.1002/pro.3275
|
38 |
Y., Liu M., Nguyen A. Robert (2019). Metal ions in Alzheimer’s disease: A key role or not? Acc. Chem. Res., 52 : 2026–2035
https://doi.org/10.1021/acs.accounts.9b00248
|
39 |
A. M., Fanni C. M., Vander Zanden P. V., Majewska J. Majewski E. Chi (2019). Membrane-mediated fibrillation and toxicity of the tau hexapeptide PHF6. J. Biol. Chem., 294 : 15304–15317
https://doi.org/10.1074/jbc.RA119.010003
|
40 |
H. L., Zhu C., ndez J. B., Fan F., Shewmaker J., Chen A. P. Minton (2010). Quantitative characterization of heparin binding to tau protein: implication for inducer-mediated tau filament formation. J. Biol. Chem., 285 : 3592–3599
https://doi.org/10.1074/jbc.M109.035691
|
41 |
N., Kfoury B. B., Holmes H., Jiang D. M. Holtzman M. Diamond (2012). Trans-cellular propagation of tau aggregation by fibrillar species. J. Biol. Chem., 287 : 19440–19451
https://doi.org/10.1074/jbc.M112.346072
|
42 |
R., La Joie A. V., Visani S. L., Baker J. A., Brown V., Bourakova J., Cha K., Chaudhary L., Edwards L., Iaccarino M. Janabi et al.. (2020). Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET. Sci. Transl. Med., 12 : eaau5732
https://doi.org/10.1126/scitranslmed.aau5732
|
43 |
C. C., Lee A., Nayak A., Sethuraman G. Belfort G. McRae (2007). A three-stage kinetic model of amyloid fibrillation. Biophys. J., 92 : 3448–3458
https://doi.org/10.1529/biophysj.106.098608
|
44 |
C., Iannuzzi M., Borriello G., Irace M., Cammarota A. Di Maro (2017). Vanillin affects amyloid aggregation and non-enzymatic glycation in human insulin. Sci. Rep., 7 : 15086
https://doi.org/10.1038/s41598-017-15503-5
|
45 |
H., Mirbaha D., Chen O. A., Morazova K. M., Ruff A. M., Sharma X., Liu M., Goodarzi R. V., Pappu D. W., Colby H. Mirzaei et al.. (2018). Inert and seed-competent tau monomers suggest structural origins of aggregation. eLife, 7 : e36584
https://doi.org/10.7554/eLife.36584
|
46 |
S. L., Shammas G. A., Garcia S., Kumar M., Kjaergaard M. H., Horrocks N., Shivji E., Mandelkow T. P., Knowles E. Mandelkow (2015). A mechanistic model of tau amyloid aggregation based on direct observation of oligomers. Nat. Commun., 6 : 7025
https://doi.org/10.1038/ncomms8025
|
47 |
M., Kjaergaard A. J., Dear F., Kundel S., Qamar G., Meisl T. P. J. Knowles (2018). Oligomer diversity during the aggregation of the repeat region of tau. ACS Chem. Neurosci., 9 : 3060–3071
https://doi.org/10.1021/acschemneuro.8b00250
|
48 |
A. Y., Roman F., Devred D., Byrne R., La Rocca N. N., Ninkina V. Peyrot P. Tsvetkov (2019). Zinc induces temperature-dependent reversible self-assembly of tau. J. Mol. Biol., 431 : 687–695
https://doi.org/10.1016/j.jmb.2018.12.008
|
49 |
S. K., Sonawane H., Chidambaram D., Boral N. V., Gorantla A. A., Balmik A., Dangi S., Ramasamy U. K. Marelli (2020). EGCG impedes human tau aggregation and interacts with Tau. Sci. Rep., 10 : 12579
https://doi.org/10.1038/s41598-020-69429-6
|
50 |
G. Ramachandran J. Udgaonkar (2011). Understanding the kinetic roles of the inducer heparin and of rod-like protofibrils during amyloid fibril formation by tau protein. J. Biol. Chem., 286 : 38948–38959
https://doi.org/10.1074/jbc.M111.271874
|
51 |
C. N., Chirita E. E., Congdon H. Yin (2005). Triggers of full-length tau aggregation: a role for partially folded intermediates. Biochemistry, 44 : 5862–5872
https://doi.org/10.1021/bi0500123
|
52 |
Y., Luo P., Dinkel X., Yu M., Margittai J., Zheng R., Nussinov G. Wei (2013). Molecular insights into the reversible formation of tau protein fibrils. Chem. Commun. (Camb.), 49 : 3582–3584
https://doi.org/10.1039/c3cc00241a
|
53 |
M., Goedert D. S. Eisenberg R. Crowther (2017). Propagation of tau aggregates and neurodegeneration. Annu. Rev. Neurosci., 40 : 189–210
https://doi.org/10.1146/annurev-neuro-072116-031153
|
54 |
A. W. P., Fitzpatrick B., Falcon S., He A. G., Murzin G., Murshudov H. J., Garringer R. A., Crowther B., Ghetti M. Goedert S. H. Scheres (2017). Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature, 547 : 185–190
https://doi.org/10.1038/nature23002
|
55 |
B., Falcon W., Zhang M., Schweighauser A. G., Murzin R., Vidal H. J., Garringer B., Ghetti S. H. W. Scheres (2018). Tau filaments from multiple cases of sporadic and inherited Alzheimer’s disease adopt a common fold. Acta Neuropathol., 136 : 699–708
https://doi.org/10.1007/s00401-018-1914-z
|
56 |
M., Goedert B., Falcon W., Zhang B. Ghetti S. H. Scheres (2018). Distinct conformers of assembled tau in Alzheimer’s and Pick’s diseases. Cold Spring Harb. Symp. Quant. Biol., 83 : 163–171
https://doi.org/10.1101/sqb.2018.83.037580
|
57 |
B., Falcon W., Zhang A. G., Murzin G., Murshudov H. J., Garringer R., Vidal R. A., Crowther B., Ghetti S. H. W. Scheres (2018). Structures of filaments from Pick’s disease reveal a novel tau protein fold. Nature, 561 : 137–140
https://doi.org/10.1038/s41586-018-0454-y
|
58 |
B., Qi S., Jin H. Qian (2020). Bibliometric analysis of chronic traumatic encephalopathy research from 1999 to 2019. Int. J. Environ. Res. Public Health, 17 : 5411
https://doi.org/10.3390/ijerph17155411
|
59 |
B., Falcon J., Zivanov W., Zhang A. G., Murzin H. J., Garringer R., Vidal R. A., Crowther K. L., Newell B., Ghetti M. Goedert et al.. (2019). Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. Nature, 568 : 420–423
https://doi.org/10.1038/s41586-019-1026-5
|
60 |
N., Sergeant A. Wattez (1999). Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively “exon 10” isoforms. J. Neurochem., 72 : 1243–1249
https://doi.org/10.1046/j.1471-4159.1999.0721243.x
|
61 |
W., Zhang A., Tarutani K. L., Newell A. G., Murzin T., Matsubara B., Falcon R., Vidal H. J., Garringer Y., Shi T. Ikeuchi et al.. (2020). Novel tau filament fold in corticobasal degeneration. Nature, 580 : 283–287
https://doi.org/10.1038/s41586-020-2043-0
|
62 |
M. D., Mukrasch M., von Bergen J., Biernat D., Fischer C., Griesinger E. Mandelkow (2007). The “jaws” of the tau-microtubule interaction. J. Biol. Chem., 282 : 12230–12239
https://doi.org/10.1074/jbc.M607159200
|
63 |
M. D., Mukrasch S., Bibow J., Korukottu S., Jeganathan J., Biernat C., Griesinger E. Mandelkow (2009). Structural polymorphism of 441-residue tau at single residue resolution. PLoS Biol., 7 : e34
https://doi.org/10.1371/journal.pbio.1000034
|
64 |
D., Chen K. W., Drombosky Z., Hou L., Sari O. M., Kashmer B. D., Ryder V. A., Perez D. R., Woodard M. M., Lin M. I. Diamond et al.. (2019). Tau local structure shields an amyloid-forming motif and controls aggregation propensity. Nat. Commun., 10 : 2493
https://doi.org/10.1038/s41467-019-10355-1
|
65 |
R., Nelson M. R., Sawaya M., Balbirnie A. O., Madsen C., Riekel R. Grothe (2005). Structure of the cross-beta spine of amyloid-like fibrils. Nature, 435 : 773–778
https://doi.org/10.1038/nature03680
|
66 |
M. R., Sawaya S., Sambashivan R., Nelson M. I., Ivanova S. A., Sievers M. I., Apostol M. J., Thompson M., Balbirnie J. J., Wiltzius H. T. McFarlane et al.. (2007). Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature, 447 : 453–457
https://doi.org/10.1038/nature05695
|
67 |
V. G., KrishnaKumar A., Paul E. Gazit (2018). Mechanistic insights into remodeled tau-derived PHF6 peptide fibrils by Naphthoquinone-Tryptophan hybrids. Sci. Rep., 8 : 71
https://doi.org/10.1038/s41598-017-18443-2
|
68 |
S. A., Sievers J., Karanicolas H. W., Chang A., Zhao L., Jiang O., Zirafi J. T., Stevens J., nch D. Baker (2011). Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature, 475 : 96–100
https://doi.org/10.1038/nature10154
|
69 |
M., Chemerovski-Glikman M., Frenkel-Pinter R., Mdah A., Abu-Mokh E. Gazit (2017). Inhibition of the aggregation and toxicity of the minimal amyloidogenic fragment of tau by its pro-substituted analogues. Chemistry, 23 : 9618–9624
https://doi.org/10.1002/chem.201701218
|
70 |
M., Pickhardt T., Neumann D., Schwizer K., Callaway M., Vendruscolo D., Schenk P., St George-Hyslop E. M., Mandelkow C. M., Dobson L. McConlogue et al.. (2015). Identification of small molecule inhibitors of tau aggregation by targeting monomeric tau as a potential therapeutic approach for tauopathies. Curr. Alzheimer Res., 12 : 814–828
https://doi.org/10.2174/156720501209151019104951
|
71 |
E. J., Davidowitz P. K., Krishnamurthy P., Lopez H., Jimenez L., Adrien P. Davies J. Moe (2020). In vivo validation of a small molecule inhibitor of tau self-association in htau mice. J. Alzheimers Dis., 73 : 147–161
https://doi.org/10.3233/JAD-190465
|
72 |
F., Kundel S., De P., Flagmeier M. H., Horrocks M., Kjaergaard S. L., Shammas S. E., Jackson C. M. Dobson (2018). Hsp70 inhibits the nucleation and elongation of tau and sequesters tau aggregates with high affinity. ACS Chem. Biol., 13 : 636–646
https://doi.org/10.1021/acschembio.7b01039
|
73 |
P. M., Seidler D. R., Boyer K. A., Murray T. P., Yang M., Bentzel M. R., Sawaya G., Rosenberg D., Cascio C. K., Williams K. L. Newell et al.. (2019). Structure-based inhibitors halt prion-like seeding by Alzheimer’s disease-and tauopathy-derived brain tissue samples. J. Biol. Chem., 294 : 16451–16464
https://doi.org/10.1074/jbc.RA119.009688
|
74 |
G., Larbig M., Pickhardt D. G., Lloyd B. Schmidt (2007). Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping. Curr. Alzheimer Res., 4 : 315–323
https://doi.org/10.2174/156720507781077250
|
75 |
G. K., Viswanathan D., Shwartz Y., Losev E., Arad C., Shemesh E., Pichinuk H., Engel A., Raveh R., Jelinek I. Cooper et al.. (2020). Purpurin modulates tau-derived VQIVYK fibrillization and ameliorates Alzheimer’s disease-like symptoms in animal model. Cell. Mol. Life Sci., 77 : 2795–2813
https://doi.org/10.1007/s00018-019-03312-0
|
76 |
Y., Porat A. Abramowitz (2006). Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des., 67 : 27–37
https://doi.org/10.1111/j.1747-0285.2005.00318.x
|
77 |
N., Bijari S., Balalaie V., Akbari F., Golmohammadi S., Moradi H. Adibi (2018). Effective suppression of the modified PHF6 peptide/1N4R Tau amyloid aggregation by intact curcumin, not its degradation products: Another evidence for the pigment as preventive/therapeutic “functional food”. Int. J. Biol. Macromol., 120 : 1009–1022
https://doi.org/10.1016/j.ijbiomac.2018.08.175
|
78 |
J. S., Rane P. Bhaumik (2017). Curcumin inhibits tau aggregation and disintegrates preformed tau filaments in vitro. J. Alzheimers Dis., 60 : 999–1014
https://doi.org/10.3233/JAD-170351
|
79 |
P., Anand A. B., Kunnumakkara R. A. Newman B. Aggarwal (2007). Bioavailability of curcumin: problems and promises. Mol. Pharm., 4 : 807–818
https://doi.org/10.1021/mp700113r
|
80 |
F., Lo Cascio N., Puangmalai A., Ellsworth F., Bucchieri A., Pace A. Palumbo Piccionello (2019). Toxic tau oligomers modulated by novel curcumin derivatives. Sci. Rep., 9 : 19011
https://doi.org/10.1038/s41598-019-55419-w
|
81 |
R., Sato S., Vohra S., Yamamoto K., Suzuki K., Pavel S., Shulga Y. Blume (2020). Specific interactions between tau protein and curcumin derivatives: Molecular docking and ab initio molecular orbital simulations. J. Mol. Graph. Model., 98 : 107611
https://doi.org/10.1016/j.jmgm.2020.107611
|
82 |
M., Okuda I., Hijikuro Y., Fujita X., Wu S., Nakayama Y., Sakata Y., Noguchi M., Ogo S., Akasofu Y. Ito et al.. (2015). PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo. PLoS One, 10 : e0117511
https://doi.org/10.1371/journal.pone.0117511
|
83 |
M., Okuda I., Hijikuro Y., Fujita T., Teruya H., Kawakami T. Takahashi (2016). Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors. Bioorg. Med. Chem. Lett., 26 : 5024–5028
https://doi.org/10.1016/j.bmcl.2016.08.092
|
84 |
W., Liu X., Hu L., Zhou Y., Tu S. Shi (2020). Orientation-inspired perspective on molecular inhibitor of tau aggregation by curcumin conjugated with ruthenium(ii) complex scaffold. J. Phys. Chem. B, 124 : 2343–2353
https://doi.org/10.1021/acs.jpcb.9b11705
|
85 |
K. C., Yu P., Kwan S. K. K., Cheung A. Ho (2018). Effects of resveratrol and morin on insoluble tau in tau transgenic mice. Transl. Neurosci., 9 : 54–60
https://doi.org/10.1515/tnsci-2018-0010
|
86 |
X. Y., Sun Q. X., Dong J., Zhu X., Sun L. F., Zhang M., Qiu X. L. Yu R. Liu (2019). Resveratrol rescues tau-induced cognitive deficits and neuropathology in a mouse model of tauopathy. Curr. Alzheimer Res., 16 : 710–722
https://doi.org/10.2174/1567205016666190801153751
|
87 |
G. M., Pasinetti J., Wang L., Ho W. Zhao (2015). Roles of resveratrol and other grape-derived polyphenols in Alzheimer’s disease prevention and treatment. Biochim. Biophys. Acta, 1852 : 1202–1208
https://doi.org/10.1016/j.bbadis.2014.10.006
|
88 |
A., Cornejo F., Aguilar Sandoval L., Caballero L., Machuca P., oz J., Caballero G., Perry A., Ardiles C. Areche (2017). Rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to β sheet in tau protein linked to Alzheimer’s disease. J. Enzyme Inhib. Med. Chem., 32 : 945–953
https://doi.org/10.1080/14756366.2017.1347783
|
89 |
Y., Guo Y., Zhao Y., Nan X., Wang Y. Chen (2017). (‒)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer’s disease. Neuroreport, 28 : 590–597
https://doi.org/10.1097/WNR.0000000000000803
|
90 |
S., Kumar V. G., Krishnakumar V., Morya S. Gupta (2019). Nanobiocatalyst facilitated aglycosidic quercetin as a potent inhibitor of tau protein aggregation. Int. J. Biol. Macromol., 138 : 168–180
https://doi.org/10.1016/j.ijbiomac.2019.07.081
|
91 |
S. K., Sonawane A. A., Balmik D., Boral S. Ramasamy (2019). Baicalein suppresses repeat tau fibrillization by sequestering oligomers. Arch. Biochem. Biophys., 675 : 108119
https://doi.org/10.1016/j.abb.2019.108119
|
92 |
M., Zhang Q., Wu X., Yao J., Zhao W., Zhong Q. Liu (2019). Xanthohumol inhibits tau protein aggregation and protects cells against tau aggregates. Food Funct., 10 : 7865–7874
https://doi.org/10.1039/C9FO02133G
|
93 |
M., Pickhardt Z., Gazova M., von Bergen I., Khlistunova Y., Wang A., Hascher E. Mandelkow J. Biernat (2005). Anthraquinones inhibit tau aggregation and dissolve Alzheimer’s paired helical filaments in vitro and in cells. J. Biol. Chem., 280 : 3628–3635
https://doi.org/10.1074/jbc.M410984200
|
94 |
E., Nepovimova E., Uliassi J., Korabecny L. E., a-Altamira S., Samez A., Pesaresi G. E., Garcia M., Bartolini V., Andrisano C. Bergamini et al.. (2014). Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects. J. Med. Chem., 57 : 8576–8589
https://doi.org/10.1021/jm5010804
|
95 |
A., Cornejo F., Salgado J., Caballero R., Vargas M. Simirgiotis (2016). Secondary metabolites in ramalina terebrata detected by UHPLC/ESI/MS/MS and identification of parietin as tau protein inhibitor. Int. J. Mol. Sci., 17 : 1303
https://doi.org/10.3390/ijms17081303
|
96 |
M., Frenkel-Pinter S., Tal R., Scherzer-Attali M., Abu-Hussien I., Alyagor T., Eisenbaum E., Gazit D. Segal (2016). Naphthoquinone-tryptophan hybrid inhibits aggregation of the tau-derived peptide PHF6 and reduces neurotoxicity. J. Alzheimers Dis., 51 : 165–178
https://doi.org/10.3233/JAD-150927
|
97 |
F., Salgado J., Caballero R., Vargas A. Cornejo (2020). Continental and antarctic lichens: isolation, identification and molecular modeling of the depside tenuiorin from the Antarctic lichen Umbilicaria antarctica as tau protein inhibitor. Nat. Prod. Res., 34 : 646–650
https://doi.org/10.1080/14786419.2018.1492576
|
98 |
C. J., Shi W., Peng J. H., Zhao H. L., Yang L. L., Qu C., Wang L. Y. Kong X. Wang (2020). Usnic acid derivatives as tau-aggregation and neuroinflammation inhibitors. Eur. J. Med. Chem., 187 : 111961
https://doi.org/10.1016/j.ejmech.2019.111961
|
99 |
N. V., Gorantla R., Das F. A., Mulani H. V. Thulasiram (2019). Neem derivatives inhibits tau aggregation. J. Alzheimers Dis. Rep., 3 : 169–178
https://doi.org/10.3233/ADR-190118
|
100 |
S., Xiao Q., Wu X., Yao J., Zhang W., Zhong J., Zhao Q. Liu (2021). Inhibitory effects of isobavachalcone on tau protein aggregation, tau phosphorylation, and oligomeric tau-induced apoptosis. ACS Chem. Neurosci., 12 : 123–132
https://doi.org/10.1021/acschemneuro.0c00617
|
101 |
S., Rafiee K., Asadollahi G., Riazi S. Ahmadian A. Saboury (2017). Vitamin B12 inhibits tau fibrillization via binding to cysteine residues of tau. ACS Chem. Neurosci., 8 : 2676–2682
https://doi.org/10.1021/acschemneuro.7b00230
|
102 |
S. Ghasemzadeh G. Riazi (2020). Inhibition of tau amyloid fibril formation by folic acid: In-vitro and theoretical studies. Int. J. Biol. Macromol., 154 : 1505–1516
https://doi.org/10.1016/j.ijbiomac.2019.11.032
|
103 |
L., Kifle D. Ortiz T. Shea (2009). Deprivation of folate and B12 increases neurodegeneration beyond that accompanying deprivation of either vitamin alone. J. Alzheimers Dis., 16 : 533–540
https://doi.org/10.3233/JAD-2009-1006
|
104 |
T., Dubey N. V., Gorantla K. T. Chandrashekara (2019). Photoexcited toluidine blue inhibits tau aggregation in Alzheimer’s disease. ACS Omega, 4 : 18793–18802
https://doi.org/10.1021/acsomega.9b02792
|
105 |
E., Haj, Y. Losev, V., Guru KrishnaKumar, E., Pichinuk, H., Engel, A., Raveh, E. Gazit. (2018) Integrating in vitro and in silico approaches to evaluate the “dual functionality” of palmatine chloride in inhibiting and disassembling tau-derived VQIVYK peptide fibrils. Biochim. Biophys. Acta Gen. Subj., 1862, 1565−1575
|
106 |
C. H., Lo C. K., Lim Z., Ding S. P., Wickramasinghe A. R., Braun K. H., Ashe E., Rhoades D. D. Thomas J. Sachs (2019). Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies. Alzheimers Dement., 15 : 1489–1502
https://doi.org/10.1016/j.jalz.2019.06.4954
|
107 |
M., Halliday H., Radford K. A. M., Zents C., Molloy J. A., Moreno N. C., Verity E., Smith C. A., Ortori D. A., Barrett M. Bushell et al.. (2017). Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain, 140 : 1768–1783
https://doi.org/10.1093/brain/awx074
|
108 |
A. L., La C. M., Walsh T. C., Neylan K. A., Vossel K., Yaffe A. D., Krystal B. L. Miller (2019). Long-term trazodone use and cognition: A potential therapeutic role for slow-wave sleep enhancers. J. Alzheimers Dis., 67 : 911–921
https://doi.org/10.3233/JAD-181145
|
109 |
P., Kumar H. Kalonia (2011). Novel protective mechanisms of antidepressants against 3-nitropropionic acid induced Huntington’s-like symptoms: a comparative study. J. Psychopharmacol., 25 : 1399–1411
https://doi.org/10.1177/0269881110364269
|
110 |
T. C., Grippe B. S. B., alves L. L., Louzada J. L., Quintas J. O. S., Naves E. F. Camargos O. brega (2015). Circadian rhythm in Alzheimer disease after trazodone use. Chronobiol. Int., 32 : 1311–1314
https://doi.org/10.3109/07420528.2015.1077855
|
111 |
V., Akbari S., Ghobadi S. Mohammadi (2020). The antidepressant drug; trazodone inhibits tau amyloidogenesis: Prospects for prophylaxis and treatment of AD. Arch. Biochem. Biophys., 679 : 108218
https://doi.org/10.1016/j.abb.2019.108218
|
112 |
R., Corpas V., valos D., Porquet P., a de Frutos S. M., Franciscato Cozzolino C. Sanfeliu B. Cardoso (2018). Melatonin induces mechanisms of brain resilience against neurodegeneration. J. Pineal Res., 65 : e12515
https://doi.org/10.1111/jpi.12515
|
113 |
A. A., Balmik, R., Das, A., Dangi, N. V., Gorantla, U. K. Marelli. (2020) Melatonin interacts with repeat domain of tau to mediate disaggregation of paired helical filaments. Biochim. Biophys. Acta, Gen. Subj., 1864, 129467
|
114 |
R., Das A. A. Balmik (2020). Effect of melatonin on tau aggregation and tau-mediated cell surface morphology. Int. J. Biol. Macromol., 152 : 30–39
https://doi.org/10.1016/j.ijbiomac.2020.01.296
|
115 |
S. C., Ren, Q. F., Suo, W. T., Du, H., Pan, M. M., Yang, R. H. Wang. (2010) Quercetin permeability across blood-brain barrier and its effect on the viability of U251 cells. Sichuan Da Xue Xue Bao Yi Xue Ban (in Chinese), 41, 751–754, 759
|
116 |
S. Habtemariam (2018). Molecular pharmacology of rosmarinic and salvianolic acids: Potential seeds for Alzheimer’s and vascular dementia drugs. Int. J. Mol. Sci., 19 : 458
https://doi.org/10.3390/ijms19020458
|
117 |
J., Wang C., Tang M. G., Ferruzzi B., Gong B. J., Song E. M., Janle T. Y., Chen B., Cooper M., Varghese A. Cheng et al.. (2013). Role of standardized grape polyphenol preparation as a novel treatment to improve synaptic plasticity through attenuation of features of metabolic syndrome in a mouse model. Mol. Nutr. Food Res., 57 : 2091–2102
https://doi.org/10.1002/mnfr.201300230
|
118 |
S., Rahmani L., Mogharizadeh F., Attar S. M., Rezayat S. E. Mousavi (2018). Probing the interaction of silver nanoparticles with tau protein and neuroblastoma cell line as nervous system models. J. Biomol. Struct. Dyn., 36 : 4057–4071
https://doi.org/10.1080/07391102.2017.1407673
|
119 |
M., Zaman E., Ahmad A., Qadeer G. Rabbani R. Khan (2014). Nanoparticles in relation to peptide and protein aggregation. Int J Nanomedicine, 9 : 899–912
|
120 |
L., Niu Y., Zou Y., Lin Y., Zheng Y. Yang (2019). Regulation mechanism of nanobiointerfaces in amyloid peptide assembly and aggregation structures. Sci. Sin. Chim., 49 : 500–515
https://doi.org/10.1360/N032018-00163
|
121 |
G., Hajsalimi S., Taheri F., Shahi F., Attar H. Ahmadi (2018). Interaction of iron nanoparticles with nervous system: an in vitro study. J. Biomol. Struct. Dyn., 36 : 928–937
https://doi.org/10.1080/07391102.2017.1302819
|
122 |
M. A., Vakilinezhad A., Amini H., Akbari Javar B. F., addini Beigi Zarandi H. Montaseri (2018). Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer’s disease animal model by reducing Tau hyperphosphorylation. Daru, 26 : 165–177
https://doi.org/10.1007/s40199-018-0221-5
|
123 |
S. K., Vimal H., Zuo Z., Wang H., Wang Z. Long (2020). Self-therapeutic nanoparticle that alters tau protein and ameliorates tauopathy toward a functional nanomedicine to tackle Alzheimer’s. Small, 16 : e1906861
https://doi.org/10.1002/smll.201906861
|
124 |
S. K., Sonawane A. Ahmad (2019). Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer’s disease. ACS Omega, 4 : 12833–12840
https://doi.org/10.1021/acsomega.9b01411
|
125 |
Y., Soeda M., Saito S., Maeda K., Ishida A., Nakamura S. Kojima (2019). Methylene blue inhibits formation of tau fibrils but not of granular tau oligomers: A plausible key to understanding failure of a clinical trial for Alzheimer’s disease. J. Alzheimers Dis., 68 : 1677–1686
https://doi.org/10.3233/JAD-181001
|
126 |
J., Zhao F., Yin L., Ji C., Wang C., Shi X., Liu H., Yang X. Wang (2020). Development of a tau-targeted drug delivery system using a multifunctional nanoscale metal-organic framework for Alzheimer’s disease therapy. ACS Appl. Mater. Interfaces, 12 : 44447–44458
https://doi.org/10.1021/acsami.0c11064
|
127 |
S. Manju (2011). Hollow microcapsules built by layer by layer assembly for the encapsulation and sustained release of curcumin. Colloids Surf. B Biointerfaces, 82 : 588–593
https://doi.org/10.1016/j.colsurfb.2010.10.021
|
128 |
X., Chen L. Q., Zou J., Niu W., Liu S. F. Peng C. Liu (2015). The stability, sustained release and cellular antioxidant activity of curcumin nanoliposomes. Molecules, 20 : 14293–14311
https://doi.org/10.3390/molecules200814293
|
129 |
S., Fan Y., Zheng X., Liu W., Fang X., Chen W., Liao X., Jing M., Lei E., Tao Q. Ma et al.. (2018). Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer’s disease. Drug Deliv., 25 : 1091–1102
https://doi.org/10.1080/10717544.2018.1461955
|
130 |
C., Gao X., Chu W., Gong J., Zheng X., Xie Y., Wang M., Yang Z., Li C. Gao (2020). Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer’s disease. J. Nanobiotechnology, 18 : 71
https://doi.org/10.1186/s12951-020-00626-1
|
131 |
Y., Hu X., Hu Y., Lu S., Shi D. Yang (2020). New strategy for reducing tau aggregation cytologically by a hairpinlike molecular inhibitor, tannic acid encapsulated in liposome. ACS Chem. Neurosci., 11 : 3623–3634
https://doi.org/10.1021/acschemneuro.0c00508
|
132 |
N. A., Singh V., Bhardwaj C., Ravi N., Ramesh A. K. A. Mandal Z. Khan (2018). EGCG nanoparticles attenuate aluminum chloride induced neurobehavioral deficits, beta amyloid and tau pathology in a rat model of Alzheimer’s disease. Front. Aging Neurosci., 10 : 244
https://doi.org/10.3389/fnagi.2018.00244
|
133 |
V., Armiento A. Spanopoulou (2020). Peptide-based molecular strategies to interfere with protein misfolding, aggregation, and cell degeneration. Angew. Chem. Int. Ed. Engl., 59 : 3372–3384
https://doi.org/10.1002/anie.201906908
|
134 |
S., Rauscher S., Baud M., Miao F. W. Keeley (2006). Proline and glycine control protein self-organization into elastomeric or amyloid fibrils. Structure, 14 : 1667–1676
https://doi.org/10.1016/j.str.2006.09.008
|
135 |
S. C., Li N. K., Goto K. A. Williams C. Deber (1996). Alpha-helical, but not β-sheet, propensity of proline is determined by peptide environment. Proc. Natl. Acad. Sci. USA., 93 : 6676–6681
https://doi.org/10.1073/pnas.93.13.6676
|
136 |
G., Pandey, S., Morla, S. Kumar. (2020) Modulation of tau protein aggregation using ‘Trojan’ sequences. Biochim. Biophys. Acta, Gen. Subj., 1864, 129569
|
137 |
I. H., Cheng K., Scearce-Levie J., Legleiter J. J., Palop H., Gerstein N., Bien-Ly J., li K. H., Ashe P. J. Muchowski et al.. (2007). Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem., 282 : 23818–23828
https://doi.org/10.1074/jbc.M701078200
|
138 |
C., Dammers D., Yolcu L., Kukuk D., Willbold M., Pickhardt E., Mandelkow A. H., Horn H., Sticht M. N., Malhis N. Will et al.. (2016). Selection and characterization of tau binding D-enantiomeric peptides with potential for therapy of Alzheimer disease. PLoS One, 11 : e0167432
https://doi.org/10.1371/journal.pone.0167432
|
139 |
N. V., Gorantla L. P., Sunny K., Rajasekhar P. G., Nagaraju P. P., Cg T. Govindaraju (2021). Amyloid-β-derived peptidomimetics inhibits tau aggregation. ACS Omega, 6 : 11131–11138
https://doi.org/10.1021/acsomega.9b03497
|
140 |
R. Best (2017). Computational and theoretical advances in studies of intrinsically disordered proteins. Curr. Opin. Struct. Biol., 42 : 147–154
https://doi.org/10.1016/j.sbi.2017.01.006
|
141 |
D. Meneksedag-Erol (2019). Atomistic simulation tools to study protein self-aggregation. Methods Mol. Biol., 2039 : 243–262
https://doi.org/10.1007/978-1-4939-9678-0_17
|
142 |
K. I., Popov K. A. T., Makepeace E. V., Petrotchenko N. V. Dokholyan C. Borchers (2019). Insight into the structure of the “unstructured” tau protein. Structure, 27 : 1710–1715.e4
https://doi.org/10.1016/j.str.2019.09.003
|
143 |
L., Larini M. M., Gessel N. E., LaPointe T. D., Do M. T., Bowers S. C. Feinstein J. Shea (2013). Initiation of assembly of tau (273‒284) and its ΔK280 mutant: an experimental and computational study. Phys. Chem. Chem. Phys., 15 : 8916–8928
https://doi.org/10.1039/c3cp00063j
|
144 |
V., Daebel S., Chinnathambi J., Biernat M., Schwalbe B., Habenstein A., Loquet E., Akoury K., Tepper H., ller M. Baldus et al.. (2012). β-Sheet core of tau paired helical filaments revealed by solid-state NMR. J. Am. Chem. Soc., 134 : 13982–13989
https://doi.org/10.1021/ja305470p
|
145 |
J., Adamcik A., nchez-Ferrer N., Ait-Bouziad N. P., Reynolds H. A. Lashuel (2016). Microtubule-binding R3 fragment from tau self-assembles into giant multistranded amyloid ribbons. Angew. Chem. Int. Ed. Engl., 55 : 618–622
https://doi.org/10.1002/anie.201508968
|
146 |
H., Liu H., Zhong Z., Xu Q., Zhang S. J. A., Shah H. Liu (2020). The misfolding mechanism of the key fragment R3 of tau protein: a combined molecular dynamics simulation and Markov state model study. Phys. Chem. Chem. Phys., 22 : 10968–10980
https://doi.org/10.1039/C9CP06954B
|
147 |
X., Li X., Dong G., Wei M., Margittai R. Nussinov (2018). The distinct structural preferences of tau protein repeat domains. Chem. Commun. (Camb.), 54 : 5700–5703
https://doi.org/10.1039/C8CC01263F
|
148 |
F. X., Smit J. A. Luiken P. Bolhuis (2017). Primary fibril nucleation of aggregation prone tau fragments PHF6 and PHF6*. J. Phys. Chem. B, 121 : 3250–3261
https://doi.org/10.1021/acs.jpcb.6b07045
|
149 |
H., Liu H., Zhong X., Liu S., Zhou S., Tan H. Liu (2019). Disclosing the mechanism of spontaneous aggregation and template-induced misfolding of the key hexapeptide (PHF6) of tau protein based on molecular dynamics simulation. ACS Chem. Neurosci., 10 : 4810–4823
https://doi.org/10.1021/acschemneuro.9b00488
|
150 |
N. A., Eschmann E. R., Georgieva P., Ganguly P. P., Borbat M. D., Rappaport Y., Akdogan J. H., Freed J. E. Shea (2017). Signature of an aggregation-prone conformation of tau. Sci. Rep., 7 : 44739
https://doi.org/10.1038/srep44739
|
151 |
J. P., Guo T., Arai J. Miklossy P. McGeer (2006). Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA, 103 : 1953–1958
https://doi.org/10.1073/pnas.0509386103
|
152 |
A. V., Rojas G. G. Maisuradze H. Scheraga (2018). Dependence of the formation of tau and Aβ peptide mixed aggregates on the secondary structure of the N-terminal region of Aβ. J. Phys. Chem. B, 122 : 7049–7056
https://doi.org/10.1021/acs.jpcb.8b04647
|
153 |
Y., Miller B. Ma (2011). Synergistic interactions between repeats in tau protein and Aβ amyloids may be responsible for accelerated aggregation via polymorphic states. Biochemistry, 50 : 5172–5181
https://doi.org/10.1021/bi200400u
|
154 |
T. D., Do N. J., Economou A., Chamas S. K., Buratto J. E. Shea M. Bowers (2014). Interactions between amyloid-β and Tau fragments promote aberrant aggregates: implications for amyloid toxicity. J. Phys. Chem. B, 118 : 11220–11230
https://doi.org/10.1021/jp506258g
|
155 |
W. S., Shin J., Di K. A., Murray C., Sun B., Li G. Bitan (2019). Different amyloid-beta self-assemblies have distinct effects on intracellular tau aggregation. Front. Mol. Neurosci., 12 : 268
https://doi.org/10.3389/fnmol.2019.00268
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|